Nickel Allergy of the Skin and Beyond
https://pubmed.ncbi.nlm.nih.gov/32108006-nickel-allergy-of-the-skin-and-beyond/?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/32108006?dopt=Abstract
http://www.eurekaselect.com/179835/article
Nickel Allergy of the Skin and Beyond.
Endocr Metab Immune Disord Drug Targets. 2020 Feb 28;:
Authors: Gergovska M, Darlenski R, Kazandjieva J
BACKGROUND: Hypersensitization to nickel is one of the most common contact allergies in the modern world and it is considered to be a major cause of contact dermatitis, especially for hand eczema.
OBJECTIVE: To describe the many faces of the nickel allergy and to find out different diagnostic, potential strategies for treatment and prevention in hypersensitized patients. A personal clinical experience with practical clinical cases of contact dermatitis to nickel is presented.
METHODS: Electronic databases on this topic was carried out using PubMed-Medline.
RESULTS: The literature review identified many articles reporting for nickel contact allergy and pointing the metal as number one allergen in the frequency of positive skin patch test reactions in large population worldwide. Herein a summary of the current understanding and evidence on nickel allergy with practical approach and proposed recommendations to the dermatologist, general practitioner, and the allergist were prepared.
CONCLUSIONS: The prevalence of nickel allergy represents an important socio-economical and health issue. The metal is the one of the most common sensitizing agents worldwide. The morbidity due to this metal represents the allergic contact dermatitis and it is constantly growing in many countries. There are also cases of systemic allergic contact dermatitis, where they could be easily misdiagnosed as adverse drug reactions, which lead to delay of the correct diagnosis and inappropriate treatment.
PMID: 32108006 [PubMed – as supplied by publisher]
PubMed:32108006
DATE FOUND:
LINK / URL:
Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis
https://stm.sciencemag.org/content/12/532/eaay1005
Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis.
J Asthma Allergy. 2020;13:109-114
Authors: Loh TY, Hsiao JL, Shi VY
Background: Atopic dermatitis (AD) is a chronic, relapsing skin condition with a wide disease spectrum. Moderate-to-severe cases often need systemic treatment. Conventional immunosuppressants have extensive side effect profiles and require close monitoring. In recent decades, there has been increasing interest in developing targeted systemic immunomodulators for AD, as they have been shown to have efficacy for AD as well as favorable safety profiles. Herein, we review the recent data on lebrikizumab, an interleukin (IL)-13 inhibitor, and its potential role in the treatment of AD.
Objective: Review the mechanism of action, and available data on the efficacy and safety of lebrikizumab for the treatment of AD.
Methods: PubMed, Google Scholar, and clinicaltrials.gov searches were performed with the following terms: "atopic dermatitis," "dermatitis," "eczema," "lebrikizumab," "IL-4," and "IL-13."
Results: Two Phase II randomized controlled clinical trials have been conducted to evaluate the use of lebrikizumab in a total of 289 patients with moderate-severe AD and inadequate response to topical corticosteroids. Patients treated with lebrikizumab experienced significantly more improvement in their AD compared to placebo, as measured by Eczema Area and Severity Index (EASI)-50 and EASI-75 scores, pruritus scores, and reduction in body surface area (BSA). Its clinical efficacy appears to be dose-dependent, and it has a favorable side effect profile and is generally well tolerated.
Conclusion: Lebrikizumab appears to be a promising emerging targeted biologic for the treatment of moderate-to-severe AD. Further Phase III studies investigating optimal dosing regimens and safety profile are needed.
PMID: 32104006 [PubMed]
Combined use of topical corticosteroids is recommended for chronic hand eczema patients being treated with oral alitretinoin due to clinically rapid and superior effectiveness
https://onlinelibrary.wiley.com/doi/abs/10.1111/1346-8138.15071
Efficacy of alitretinoin depending on the concomitant use of topical corticosteroids in chronic hand eczema patients.
J Dermatol. 2019 Sep 18;:
Authors: Cheon DU, Kim JE, Ko JY, Ro YS
Alitretinoin is the only systemic agent approved for the treatment of severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids. Clinical trials have shown the efficacy of oral alitretinoin with topical emollients for CHE treatment, but most studies have failed to reach a therapeutic success rate of 50%. Reasonably, we thought it would be more effective to combine topical corticosteroids with oral alitretinoin, but the concomitant use of topical corticosteroids has not been studied yet. One-hundred and seven Korean patients diagnosed with CHE were recruited. The participants were divided into two groups depending on the concomitant use of topical corticosteroids. Comparative analysis was performed between the combined therapy (alitretinoin and topical corticosteroids) and monotherapy groups (alitretinoin only) by using physician global assessment (PGA), patient's global assessment (PaGA), modified total lesion symptom score (mTLSS), and recurrence rates. The combined therapy group showed a significantly higher treatment success rate than the alitretinoin monotherapy group for all efficacy parameters (PGA: P < 0.001, PaGA: P < 0.001, mTLSS changes: P < 0.001), but there was no significant difference in recurrence rates between the groups (P = 0.266). Combined use of topical corticosteroids is recommended for CHE patients being treated with oral alitretinoin due to clinically rapid and superior effectiveness. PMID: 31535403 [PubMed - as supplied by publisher] PMID: PubMed:31535403 DATE FOUND: 09/21/19 01:17PM LINK / URL: https://www.ncbi.nlm.nih.gov/pubmed/31535403?dopt=Abstract
Treatment of non-atopic dermatitis with polarized UV-free polychromatic light: A case report
Treatment of non-atopic dermatitis with polarized UV-free polychromatic light: A case report.
Clin Pract. 2019 Aug 02;9(3):1161
Authors: Leguina-Ruzzi A, Raichura KR, Tonks SK, Kwabi S, Leitner C
Non-atopic dermatitis is a common inflammatory condition, which is potentially debilitating and can compromise life quality. Polarized ultraviolet-free polychromatic light is used as therapeutic option for the treatment of wound healing and dermatological conditions. It has not yet been tested in the management of non-atopic dermatitis. In this case report, we present a 67- year-old female patient who had suffered with moderate non-atopic dermatitis for the past 20 years, and had undergone multiple treatments during that time without significant improvement or relief from her symptoms. She was treated for six weeks only with daily light therapy applications (10 minutes/area). Our results showed that light therapy offered a significant reduction in erythema of the affected zones with a concomitant reduction in pruritus and dehydration of the skin, without side effects or discomfort.
Apple cider vinegar soaks [0.5%] as a treatment for atopic dermatitis do not improve skin barrier integrity
https://onlinelibrary.wiley.com/doi/full/10.1111/pde.13888
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis